When completed, AV001 will be the first blinded randomized controlled trial in post-surgical neuropathic pain that evaluates the long term treatment effects of a topical neuropathic pain treatment.
When completed, AV001 will be the first blinded randomized controlled trial in post-surgical neuropathic pain that evaluates the long term treatment effects of a topical neuropathic pain treatment.
Applications are now open for new users from 28 October to 19 November. Please refer to the ‘Access for 2025 and support packages’ section below. The Early Years Assessment and Learning Tool (EYALT) ...
Gilead Sciences, Inc. announced today its third quarter 2024 results of operations. "Gilead's third quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, ...